Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Up-regulation and Antibody-Peptide Competition. Human recombinant Tau treated with PKA (36 µg per µg Tau) for 45 minutes and added to background extracts were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. The membrane was blocked with a 5% BSA-TBST buffer for one hour at room temperature, then incubated with the Tau [pS356] antibody in a 1% BSA-TBST buffer for two hours at room temperature, following prior incubation with: no peptide (1), the non-phosphopeptide corresponding to the phosphopeptide immunogen (2), a generic phosphoserine-containing peptide (3), or the phosphopeptide immunogen (4). After washing, the membrane was incubated with goat F(ab')2 anti-rabbit IgG HRP conjugate (Cat. no. ALI4404) and signals were detected using the Pierce SuperSignal™ method. The data show that only the phosphopeptide corresponding to Tau [pS356] blocks the antibody signal, demonstrating the specificity of the antibody. This antibody does not cross-react with Tau [pS262] (data not shown).
|Tested species reactivity||Mouse , Human , Rat|
|Published species reactivity||Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||The antiserum was produced against a chemically synthesized phosphopeptide derived from a region of human Tau that contains serine 356. The sequence is conserved in many species including mouse, rat, rhesus monkey, baboon, cow and goat.|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol|
|Contains||0.05% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||1-3 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
A proteomic analysis of MCLR-induced neurotoxicity: implications for Alzheimer's disease.
||Li G,Cai F,Yan W,Li C,Wang J||Toxicological sciences : an official journal of the Society of Toxicology (127:485)||2012|
MTBT2, MTBT1, TAU, DDPAC, AW045860, AI413597, RNPTAU, Tau, PPND, Mtapt, FTDP-17, pTau, MAPTL, MSTD
G protein beta1/gamma2 subunit-interacting factor 1, PHF-tau, microtubule-associated protein tau, microtubule-associated protein tau, isoform 4, neurofibrillary tangle protein, paired helical filament-tau, Tau microtubule-associated protein, MAPT, Microtubule-associated protein tau, MTBT1